**Question:** All of the following soft tissue sarcomas have a propensity for lymphatic spread except

A. Ewing's sarcoma
B. Liposarcoma
C. Angiosarcoma
D. Leiomyosarcoma

**Correct Answer:** D. Leiomyosarcoma

**Core Concept:** Soft tissue sarcomas are a group of malignant tumors that originate from mesenchymal cells, which include smooth muscle, cartilage, bone, and fat cells. These tumors can exhibit various patterns of spread, including lymphatic, hematogenous, or direct invasion.

**Why the Correct Answer is Right:** Leiomyosarcoma is a type of soft tissue sarcoma that primarily arises from smooth muscle cells. Although it can spread through blood vessels (hematogenous), it typically lacks the capacity for direct invasion into adjacent tissues, which means it does not commonly spread to lymph nodes. In contrast, the other options are known for their potential to spread via the lymphatic system.

**Why Each Wrong Option is Incorrect:**

A. Ewing's sarcoma is a type of bone sarcoma that can also involve soft tissues. It commonly spreads to lymph nodes due to its propensity for direct invasion into adjacent tissues.

B. Liposarcoma is a type of soft tissue sarcoma that can spread to lymph nodes, especially in cases of deep or large tumors.

C. Angiosarcoma is a rare and aggressive type of soft tissue sarcoma that originates from vascular endothelial cells. It has a high potential for lymphatic spread.

**Why the Correct Answer is Right:** Leiomyosarcoma's primary spread is hematogenous, making it less likely to spread to lymph nodes compared to the other options. This understanding is crucial for clinical practice, as the choice of treatment, surveillance, and prognosis can be influenced by the pattern of spread.

**Clinical Pearl:** In clinical practice, distinguishing between different types of soft tissue sarcomas is essential for appropriate staging, treatment planning, and patient management. Adequate knowledge of the distinct patterns of spread (lymphatic, hematogenous, or direct invasion) allows for a more targeted approach to treatment and surveillance, potentially improving patient outcomes.